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Abstract
Background: Mice with a deleted Gpihbp1 gene encoding glycosylphosphatidylinositol-anchored
high-density lipoprotein-binding protein 1 (GPI-HBP1) develop severe chylomicronemia. We
screened the coding regions of the human homologue – GPIHBP1 – from the genomic DNA of 160
unrelated adults with fasting chylomicronemia and plasma triglycerides >10 mmol/L, each of whom
had normal sequence of the LPL and APOC2 genes.
Results:  One patient with severe type 5 hyperlipoproteinemia (MIM 144650), fasting
chylomicronemia and relapsing pancreatitis resistant to standard therapy was found to be
homozygous for a novel GPIHBP1 missense variant, namely G56R. This mutation was absent from
the genomes of 600 control subjects and 610 patients with hyperlipidemia. The GPIHBP1 G56
residue has been conserved throughout evolution and the G56R mutation was predicted to have
compromised function. Her homozygous brother also had refractory chylomicronemia and
relapsing pancreatitis together with early coronary heart disease. G56R heterozygotes in the family
had fasting mild hypertriglyceridemia.
Conclusion: Thus, a very rare GPIHBP1 missense mutation appears to be associated with severe
hypertriglyceridemia and chylomicronemia.
Background
Glycosylphosphatidylinositol (GPI)-anchored high-den-
sity lipoprotein (HDL)-binding protein 1 (GPIHBP1) was
identified by expression cloning as a cell surface protein
that bound high-density lipoprotein (HDL) [1]. Recently,
mice with induced deficiency in Gpihbp1 showed compro-
mised lipolysis leading to severe chylomicronemia, even
on a low-fat diet [2]. GPIHBP1 appears to provide a criti-
cal platform for the binding of both lipoprotein lipase
(LPL) and chylomicrons [1,2]. Since no human mutations
in  GPIHBP1  have yet been reported, we screened the
genomic DNA of 160 unrelated adults with fasting chy-
lomicronemia to search for coding sequence mutations in
this gene.
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Results
Demographics of study sample
From a tertiary referral lipid clinic, we evaluated 160
patients (33% female, 35% with diabetes) who had fast-
ing chylomicronemia on at least one occasion. Age, body
mass index, untreated fasting plasma cholesterol and trig-
lycerides (mean ± standard deviation [SD]) were, respec-
tively, 50.5 ± 13.8 years, 30.2 ± 4.8 kg/m2, 11.9 ± 6.0
mmol/L and 31.1 ± 25.0 mmol/L. All subjects consented
to DNA analysis. No coding sequence mutations were
found in LPL and APOC2 genes encoding, respectively,
lipoprotein lipase and apolipoprotein (apo) C-II.
Characterization of family with GPIHBP1 mutation
Only one rare coding sequence variant in GPIHBP1 was
found among the 160 screened patients, namely G56R
(Figure 1A). This missense mutation was absent from the
genomes of 600 normolipidemic Caucasian control sub-
jects and 610 Caucasian patients with hyperlipidemia.
The mutated amino acid residue was evolutionarily con-
served (Figure 1B) and analysis with the PolyPhen algo-
rithm [3] indicated that the mutation was probably
damaging.
The proband, a homozygote for GPIHBP1  G56R, had
relapsing pancreatitis beginning at age 22 and was docu-
mented on numerous occasions to refractory fasting chy-
lomicronemia, even with fat restriction. She had no
thyroid, renal or hepatic disease and was not diabetic. She
was not obese and consumed no alcohol. Her older
brother had a similar biochemical profile, with a history
of relapsing pancreatitis requiring hospitalization, refrac-
tory to medical treatment since age 25. At age 45 he
required 3-vessel coronary artery bypass graft surgery for
unstable angina symptoms that began at age 44 (Figure
1C).
Both patients had normal activities of lipoprotein and
hepatic lipases in post-heparin plasma, indicating that ex
vivo lipolytic activity was not compromised. Both parents
were long-deceased. Although consanguinity was not doc-
umented, it was possible since both parents were born in
the same village. Three heterozygotes in this pedigree each
had plasma triglyceride concentration in the top 5th per-
centile for age and sex, but no history of pancreatic or car-
diovascular disease. Further, the proband's untreated son
had combined hyperlipidemia, with approximately equi-
molar elevations of plasma total cholesterol and triglycer-
ides, which together with an APOE E2/E2 genotype were
highly suggestive of type 3 hyperlipoproteinemia (dysbe-
talipoproteinemia). Both patients have had a variable
response to oral fibrate therapy, with a somewhat better
response to restriction of fat intake to 20% of calories and
to omega-3 fatty acids, although long term compliance
Molecular genetic studies of GPIHBP1 Figure 1
Molecular genetic studies of GPIHBP1. A) DNA sequence analysis of GPIHBP1 exon 2 from genomic DNA of a normolipidemic subject (upper trac-
ing), a G56R heterozygote (middle tracing) and the homozygote proband (lower tracing). For each tracing, normal nucleotide sequence is shown in the top 
line of letters, with single letter amino acid codes and codon numbers beneath. The position of the mutated nucleotide is indicated by the arrow. B) Evo-
lutionary conservation of human GPIHBP1 G56 in primates and rodents; the single letter amino acid codes and peptide position for the homologous region 
from each species are shown. C) Nuclear family of the proband with severe type V hyperlipoproteinemia and fasting chylomicronemia. 
The proband (identification [ID] number II-3) and her older affected brother (ID II-1) are indicated with solid symbols. Genotype-proven heterozygotes 
are shown with half-solid symbols. Patient age and plasma concentrations of total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol 
(HDL-C) and low-density lipoprotein cholesterol (LDL-C), all in millimoles per litre (mM), and of apolipoprotein (apo) A-I and B, in grams per litre (g/L), 
are shown. ND means the value could not be determined. A documented history of hospitalization for pancreatitis and coronary heart disease (CHD) are 
shown. Genotypes of the GBPHBP1 exon 2 G56R mutation and of common APOE isoforms are shown.
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has been an issue. Plasma triglyceride concentration was
never <10 mmol/L in either patient over since their diag-
nosis.
Discussion
The recent characterization of a focal role for Gpihbp1 in
murine triglyceride metabolism was a significant develop-
ment in the lipoprotein field [2]. Our genetic findings sug-
gest that GPIHBP1 might also have an important role in
human triglyceride metabolism, albeit only one missense
mutation in GPIHBP1 – G56R – was found among 160
patients with an analogous phenotype to mice with a
deleted Gpihbp1 gene, namely severe type 5 hyperlipopro-
teinemia, fasting chylomicronemia and a normal coding
sequence of LPL and APOC2 genes. The G56R mutation
altered a highly conserved residue and functional com-
promise was predicted. The mutation was associated in
homozygotes with severe, refractory hypertriglyceridemia.
In heterozygotes, the mutation was associated with mild
to moderate hypertriglyceridemia, and very likely with
type 3 hyperlipoproteinemia in a subject who was also
homozygous for APOE  E2/E2. Furthermore, the G56R
mutation was absent from large numbers of normolipi-
demic control subjects and also from a large number of
patients referred to a tertiary clinic for management of a
wide range of hyperlipidemia phenotypes.
Conclusion
The association of this coding sequence variant with
severe type 5 hyperlipoproteinemia with chylomicrone-
mia, its absence from normolipidemic subjects together
with other evidence for its likely pathogenicity appears to
link the GPIHBP1 gene with severe human metabolic phe-
notypes. The fact that this was the only mutation from
hundreds of screened subjects with an appropriate disease
phenotype indicates that mutations in this gene are not
likely to be a major cause of severe hypertriglyceridemia.
Methods
Genomic DNA analysis
The exons and intron-exon boundaries of GPIHBP1 were
amplified and bi-directionally sequenced using the prim-
ers and conditions in Table 1. All coding sequence muta-
tions were confirmed by a second sequencing reaction
performed on another day. The frequency of the GPIHBP1
exon 2 G56R coding single nucleotide variant in 600 nor-
molipidemic Caucasian control subjects and 610 Cauca-
sian patients with hyperlipidemia from a tertiary referral
clinic was determined using genomic DNA amplification
with primers 5'-ATG CTT GCC CAG AGC AGG TGT C and
5'-GCC TGC TGG CTT CCA TCA CAC. The 282 bp prod-
uct was digested with restriction enzyme BstNI (New Eng-
land Biolabs, Mississauga, ON) and fragments were
resolved on 2% agarose gels. The fragments of the wild-
type G56 allele were 114, 67, 59 and 42 bp in size, while
the fragments of the R56 allele were 173, 67 and 42 bp in
size. In family members, measurements of fasting plasma
lipoproteins and apolipoproteins, APOE genotype analy-
sis and, in the two homozygotes, assessment of lipase
activities in post-heparin plasma were performed as
described [4-6].
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